Sprint Bioscience AB (publ) (SPRINT.ST)
SEK 1.6
(0.25%)
SEK 1.6
(0.25%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 62.37 Million SEK | 66.69% |
| 2022 | 37.42 Million SEK | -52.71% |
| 2021 | 79.13 Million SEK | 136.94% |
| 2020 | 33.39 Million SEK | 73.56% |
| 2019 | 19.24 Million SEK | -67.54% |
| 2018 | 59.29 Million SEK | 67.08% |
| 2017 | 35.48 Million SEK | -28.34% |
| 2016 | 49.52 Million SEK | 61.66% |
| 2015 | 30.63 Million SEK | 21.82% |
| 2014 | 25.14 Million SEK | 236.55% |
| 2013 | 7.47 Million SEK | 73.72% |
| 2012 | 4.3 Million SEK | 55.02% |
| 2011 | 2.77 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 52.31 Million SEK | -16.13% |
| 2024 Q3 | 46.02 Million SEK | -4.71% |
| 2024 Q2 | 48.3 Million SEK | -7.67% |
| 2023 Q2 | 23 Million SEK | -32.6% |
| 2023 Q4 | 62.37 Million SEK | -2.18% |
| 2023 Q3 | 63.76 Million SEK | 177.2% |
| 2023 FY | 62.37 Million SEK | 66.69% |
| 2023 Q1 | 34.13 Million SEK | -8.8% |
| 2022 Q2 | 47.7 Million SEK | -25.36% |
| 2022 FY | 37.42 Million SEK | -52.71% |
| 2022 Q4 | 37.42 Million SEK | 8.94% |
| 2022 Q3 | 34.35 Million SEK | -27.99% |
| 2022 Q1 | 63.91 Million SEK | -19.24% |
| 2021 Q3 | 95.4 Million SEK | 381.64% |
| 2021 Q1 | 17.96 Million SEK | -46.22% |
| 2021 Q4 | 79.13 Million SEK | -17.05% |
| 2021 FY | 79.13 Million SEK | 136.94% |
| 2021 Q2 | 19.8 Million SEK | 10.28% |
| 2020 Q1 | 21.06 Million SEK | 9.45% |
| 2020 Q2 | 56.62 Million SEK | 168.83% |
| 2020 Q4 | 33.39 Million SEK | -27.11% |
| 2020 Q3 | 45.82 Million SEK | -19.07% |
| 2020 FY | 33.39 Million SEK | 73.56% |
| 2019 Q4 | 19.24 Million SEK | -67.94% |
| 2019 Q1 | 62.45 Million SEK | 5.33% |
| 2019 FY | 19.24 Million SEK | -67.54% |
| 2019 Q2 | 66.81 Million SEK | 6.99% |
| 2019 Q3 | 60.02 Million SEK | -10.16% |
| 2018 Q2 | 66.45 Million SEK | -14.46% |
| 2018 FY | 59.29 Million SEK | 67.08% |
| 2018 Q4 | 59.29 Million SEK | 5.88% |
| 2018 Q3 | 55.99 Million SEK | -15.73% |
| 2018 Q1 | 77.68 Million SEK | 118.92% |
| 2017 Q4 | 35.48 Million SEK | -20.22% |
| 2017 FY | 35.48 Million SEK | -28.34% |
| 2017 Q3 | 44.47 Million SEK | 12.78% |
| 2017 Q2 | 39.43 Million SEK | -6.7% |
| 2017 Q1 | 42.26 Million SEK | -14.65% |
| 2016 Q1 | 42.64 Million SEK | 39.21% |
| 2016 Q4 | 49.52 Million SEK | -7.82% |
| 2016 FY | 49.52 Million SEK | 61.66% |
| 2016 Q3 | 53.72 Million SEK | 67.55% |
| 2016 Q2 | 32.06 Million SEK | -24.81% |
| 2015 Q3 | 35.69 Million SEK | 116.85% |
| 2015 Q4 | 30.63 Million SEK | -14.18% |
| 2015 FY | 30.63 Million SEK | 21.82% |
| 2015 Q2 | 16.46 Million SEK | -24.38% |
| 2015 Q1 | 21.76 Million SEK | -13.44% |
| 2014 Q4 | 25.14 Million SEK | 185.44% |
| 2014 FY | 25.14 Million SEK | 236.55% |
| 2014 Q1 | - SEK | -100.0% |
| 2014 Q2 | 11.66 Million SEK | 0.0% |
| 2014 Q3 | 8.81 Million SEK | -24.49% |
| 2013 Q4 | 7.47 Million SEK | 0.0% |
| 2013 Q1 | - SEK | 0.0% |
| 2013 FY | 7.47 Million SEK | 73.72% |
| 2012 FY | 4.3 Million SEK | 55.02% |
| 2011 FY | 2.77 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 118.45 Million SEK | 47.339% |
| Ziccum AB (publ) | 14.97 Million SEK | -316.624% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | -211.247% |
| BioArctic AB (publ) | 1.18 Billion SEK | 94.741% |
| Mendus AB (publ) | 755.95 Million SEK | 91.749% |
| Genovis AB (publ.) | 288.85 Million SEK | 78.406% |
| Intervacc AB (publ) | 259.61 Million SEK | 75.973% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | -48.662% |
| Active Biotech AB (publ) | 44 Million SEK | -41.766% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | 77.622% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | -0.362% |
| Aptahem AB (publ) | 63.02 Million SEK | 1.028% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | 87.43% |
| Kancera AB (publ) | 65.64 Million SEK | 4.975% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | 82.246% |
| Fluicell AB (publ) | 9.34 Million SEK | -567.848% |
| Saniona AB (publ) | 64.14 Million SEK | 2.753% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | -85.635% |
| Biovica International AB (publ) | 131.4 Million SEK | 52.532% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | -17.726% |
| AcouSort AB (publ) | 34.51 Million SEK | -80.735% |
| Xintela AB (publ) | 18.39 Million SEK | -239.098% |
| Abliva AB (publ) | 87.49 Million SEK | 28.711% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | 91.795% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 95.043% |
| OncoZenge AB (publ) | 20.34 Million SEK | -206.672% |
| Amniotics AB (publ) | 26.08 Million SEK | -139.121% |
| 2cureX AB (publ) | 16.62 Million SEK | -275.2% |
| CombiGene AB (publ) | 120.61 Million SEK | 48.283% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -926.444% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 96.718% |
| Camurus AB (publ) | 1.9 Billion SEK | 96.73% |
| Corline Biomedical AB | 100.1 Million SEK | 37.688% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | 64.783% |
| Isofol Medical AB (publ) | 140.59 Million SEK | 55.634% |
| I-Tech AB | 152.44 Million SEK | 59.082% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 93.873% |
| Cyxone AB (publ) | 43.65 Million SEK | -42.886% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | 20.733% |
| Biosergen AB | 7.2 Million SEK | -766.227% |
| Cantargia AB (publ) | 223.71 Million SEK | 72.117% |
| NextCell Pharma AB | 81.28 Million SEK | 23.264% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 91.849% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | -106.731% |
| Nanologica AB (publ) | 77.42 Million SEK | 19.44% |
| SynAct Pharma AB | 228.01 Million SEK | 72.644% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | -133.072% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | -187.414% |
| LIDDS AB (publ) | 17.65 Million SEK | -253.311% |
| Lipum AB (publ) | 12.11 Million SEK | -415.087% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 95.545% |
| Alzinova AB (publ) | 123.18 Million SEK | 49.365% |
| Oncopeptides AB (publ) | 238.37 Million SEK | 73.833% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -637.753% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | 26.811% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -319.51% |
| Simris Alg AB (publ) | 174.55 Million SEK | 64.265% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | 71.26% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | 90.455% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | 28.362% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | -118.805% |